JP6549703B2 - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP6549703B2
JP6549703B2 JP2017514705A JP2017514705A JP6549703B2 JP 6549703 B2 JP6549703 B2 JP 6549703B2 JP 2017514705 A JP2017514705 A JP 2017514705A JP 2017514705 A JP2017514705 A JP 2017514705A JP 6549703 B2 JP6549703 B2 JP 6549703B2
Authority
JP
Japan
Prior art keywords
carboxamide
cyano
pyrrolidine
thiazol
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530960A5 (en:Method
JP2017530960A (ja
Inventor
アリソン・ジョーンズ
マーク・イアン・ケンプ
マーティン・リー・ストックリー
カール・リチャード・ギブソン
ギャヴィン・アリステア・ウィットロック
アンドリュー・マディン
Original Assignee
ミッション・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミッション・セラピューティクス・リミテッド filed Critical ミッション・セラピューティクス・リミテッド
Publication of JP2017530960A publication Critical patent/JP2017530960A/ja
Publication of JP2017530960A5 publication Critical patent/JP2017530960A5/ja
Priority to JP2019119342A priority Critical patent/JP6959299B2/ja
Application granted granted Critical
Publication of JP6549703B2 publication Critical patent/JP6549703B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017514705A 2014-09-23 2015-09-22 新規化合物 Active JP6549703B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019119342A JP6959299B2 (ja) 2014-09-23 2019-06-27 新規化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1416754.8 2014-09-23
GBGB1416754.8A GB201416754D0 (en) 2014-09-23 2014-09-23 Novel compounds
PCT/GB2015/052729 WO2016046530A1 (en) 2014-09-23 2015-09-22 Novel compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019119342A Division JP6959299B2 (ja) 2014-09-23 2019-06-27 新規化合物

Publications (3)

Publication Number Publication Date
JP2017530960A JP2017530960A (ja) 2017-10-19
JP2017530960A5 JP2017530960A5 (en:Method) 2018-11-08
JP6549703B2 true JP6549703B2 (ja) 2019-07-24

Family

ID=51869322

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017514705A Active JP6549703B2 (ja) 2014-09-23 2015-09-22 新規化合物
JP2019119342A Active JP6959299B2 (ja) 2014-09-23 2019-06-27 新規化合物
JP2021092454A Active JP7261264B2 (ja) 2014-09-23 2021-06-01 新規化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019119342A Active JP6959299B2 (ja) 2014-09-23 2019-06-27 新規化合物
JP2021092454A Active JP7261264B2 (ja) 2014-09-23 2021-06-01 新規化合物

Country Status (24)

Country Link
US (5) US9926307B2 (en:Method)
EP (2) EP3828179A1 (en:Method)
JP (3) JP6549703B2 (en:Method)
KR (1) KR102493967B1 (en:Method)
CN (2) CN111592534B (en:Method)
AU (1) AU2015323572B2 (en:Method)
CA (1) CA2958262C (en:Method)
CY (1) CY1122983T1 (en:Method)
DK (1) DK3197883T3 (en:Method)
ES (1) ES2798473T3 (en:Method)
GB (1) GB201416754D0 (en:Method)
HR (1) HRP20200962T1 (en:Method)
HU (1) HUE050732T2 (en:Method)
IL (1) IL250345B (en:Method)
LT (1) LT3197883T (en:Method)
MX (1) MX2017003358A (en:Method)
PL (1) PL3197883T3 (en:Method)
PT (1) PT3197883T (en:Method)
RS (1) RS60468B1 (en:Method)
RU (1) RU2691389C2 (en:Method)
SG (1) SG11201700847YA (en:Method)
SI (1) SI3197883T1 (en:Method)
SM (1) SMT202000323T1 (en:Method)
WO (1) WO2016046530A1 (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019178161A (ja) * 2014-09-23 2019-10-17 ミッション・セラピューティクス・リミテッド 新規化合物

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190407T1 (hr) 2014-06-19 2019-05-03 Ariad Pharmaceuticals, Inc. Heteroarilni spojevi za inhibiciju kinaza
SMT202100287T1 (it) 2015-03-30 2021-07-12 Mission Therapeutics Ltd Composti 1-ciano-pirrolidinici come inibitori di usp30
CA2990583A1 (en) * 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
EP3322702B1 (en) * 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
WO2017184751A1 (en) * 2016-04-20 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing hypertension
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN109790112B (zh) * 2016-09-27 2022-08-26 特殊治疗有限公司 具有作为usp30抑制剂活性的氰基吡咯烷衍生物
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN110198937A (zh) * 2017-02-14 2019-09-03 华东理工大学 N-(5-吗啉代噻唑-2-基)甲酰胺类化合物及其制备方法和用途
AU2018265397A1 (en) * 2017-05-10 2019-11-28 Cortexyme, Inc. Aminopyridine compounds and methods for the preparation and use thereof
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
JP7208931B2 (ja) * 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
JP7336434B2 (ja) * 2017-08-01 2023-08-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2019084497A1 (en) * 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
AR114422A1 (es) 2018-03-30 2020-09-02 Syngenta Participations Ag Compuestos herbicidas
MX2020012063A (es) 2018-05-14 2021-04-13 Takeda Pharmaceuticals Co Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos.
AU2019271279A1 (en) * 2018-05-17 2020-11-26 Forma Therapeutics, Inc. Fused bicyclic compounds useful as Ubiquitin-Specific Peptidase 30 inhibitors
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
US12252490B2 (en) 2018-08-09 2025-03-18 Valo Health, Inc. Inhibiting deubiquitinase USP25 and USP28
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
BR112021003620A2 (pt) 2018-10-05 2021-05-18 Forma Therapeutics, Inc. pirrolinas fundidas que atuam como inibidoras da protease específica para a ubiquitina 30 (usp30)
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
KR102397752B1 (ko) * 2019-06-19 2022-05-16 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
GB201912674D0 (en) * 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
EP4054554A1 (en) 2019-11-05 2022-09-14 Dermira, Inc Mrgprx2 antagonists for the treatment of inflammatory disorders
US20230119013A1 (en) 2020-04-08 2023-04-20 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021242955A1 (en) * 2020-05-28 2021-12-02 Senda Biosciences, Inc. Fused azole heterocycles as ahr antagonists
CA3185027A1 (en) * 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mi tochondrial dysfunction
JP7796047B2 (ja) 2020-06-04 2026-01-08 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
CN115836073B (zh) 2020-06-08 2024-08-27 特殊治疗有限公司 用于治疗线粒体功能障碍、癌症和纤维化的作为usp30抑制剂的1-(5-(2-氰基吡啶-4-基)噁唑-2-羰基)-4-甲基六氢吡咯并[3,4-b]吡咯-5(1h)-甲腈
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
AR125588A1 (es) 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3
CA3224123A1 (en) * 2021-07-26 2023-02-02 James Griffin Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
JP2024545132A (ja) * 2021-12-10 2024-12-05 プロシーナ バイオサイエンシーズ リミテッド Ｄｙｒｋ１ａ阻害剤としての複素環化合物
AU2024301960A1 (en) * 2023-06-14 2026-01-22 Prothena Biosciences Limited Bicyclic heteroaromatic compounds for treating neurological disorders
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
CN119528901A (zh) * 2024-11-05 2025-02-28 上海市同济医院 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
AU2001256981A1 (en) * 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
WO2005089763A1 (en) 2004-03-19 2005-09-29 Warner-Lambert Company Llc Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
WO2007063934A1 (ja) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
WO2010052222A1 (en) 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
WO2010059658A1 (en) 2008-11-20 2010-05-27 Glaxosmithkline Llc Chemical compounds
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
EA026409B1 (ru) * 2011-10-19 2017-04-28 Виволюкс Аб Соединение, ингибирующее деубиквитинирующую активность, и использование его в композиции и в способе лечения рака
AU2013292519B2 (en) 2012-07-19 2017-12-07 Drexel University Sigma receptor ligands for modulating cellular protein homeostasis
AU2014259671A1 (en) 2013-05-02 2015-11-26 E3X Bio. Inc. Method for identifying modulators of ubiquitin ligases
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
SMT202100287T1 (it) 2015-03-30 2021-07-12 Mission Therapeutics Ltd Composti 1-ciano-pirrolidinici come inibitori di usp30
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019178161A (ja) * 2014-09-23 2019-10-17 ミッション・セラピューティクス・リミテッド 新規化合物

Also Published As

Publication number Publication date
AU2015323572B2 (en) 2019-09-19
RS60468B1 (sr) 2020-07-31
SG11201700847YA (en) 2017-04-27
CA2958262A1 (en) 2016-03-31
US20230052191A1 (en) 2023-02-16
US20180162852A1 (en) 2018-06-14
WO2016046530A1 (en) 2016-03-31
GB201416754D0 (en) 2014-11-05
JP2021138734A (ja) 2021-09-16
RU2017105296A3 (en:Method) 2019-01-22
CN111592534A (zh) 2020-08-28
US20200369658A1 (en) 2020-11-26
JP2017530960A (ja) 2017-10-19
US20190330202A1 (en) 2019-10-31
US10774078B2 (en) 2020-09-15
HUE050732T2 (hu) 2021-01-28
JP7261264B2 (ja) 2023-04-19
EP3197883A1 (en) 2017-08-02
AU2015323572A1 (en) 2017-03-23
HRP20200962T1 (hr) 2020-10-02
KR102493967B1 (ko) 2023-01-31
BR112017005887A2 (pt) 2017-12-12
SI3197883T1 (sl) 2020-08-31
US11472798B2 (en) 2022-10-18
US10392380B2 (en) 2019-08-27
US20170247365A1 (en) 2017-08-31
DK3197883T3 (da) 2020-06-22
CN111592534B (zh) 2023-06-30
EP3197883B1 (en) 2020-03-18
MX2017003358A (es) 2017-09-13
IL250345B (en) 2019-05-30
EP3828179A1 (en) 2021-06-02
PL3197883T3 (pl) 2020-10-19
CN107001339A (zh) 2017-08-01
SMT202000323T1 (it) 2020-07-08
US11993595B2 (en) 2024-05-28
CA2958262C (en) 2023-02-14
ES2798473T3 (es) 2020-12-11
JP6959299B2 (ja) 2021-11-02
CY1122983T1 (el) 2021-10-29
KR20170055499A (ko) 2017-05-19
US9926307B2 (en) 2018-03-27
JP2019178161A (ja) 2019-10-17
LT3197883T (lt) 2020-07-10
RU2691389C2 (ru) 2019-06-13
RU2017105296A (ru) 2018-10-24
PT3197883T (pt) 2020-06-22
CN107001339B (zh) 2020-03-17
IL250345A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
JP7261264B2 (ja) 新規化合物
JP7389856B2 (ja) Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物
JP2018524367A (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
HK1240929B (zh) 新化合物
HK1240929A1 (en) Novel compounds
HK40026813A (zh) 新化合物
HK40043421A (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
BR112017005887B1 (pt) Composto, método para produção e uso do mesmo, bem como composição farmacêutica
HK40026813B (en) Novel compounds

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170725

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180925

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190523

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190627

R150 Certificate of patent or registration of utility model

Ref document number: 6549703

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250